PE
ESPR

Point72 Europe’s Esperion Therapeutics ESPR Stock Holding History

Point72 Europe’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$17.8K Buy
+6,719
New +$13K ﹤0.01% 486

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Point72 Europe's ESPR Position: Q3 2025 in Review

Point72 Europe opened a new position in Esperion Therapeutics (ESPR) in Q3 2025: 6,719 shares worth $17.8K. The stake represents ﹤0.01% of the portfolio and ranks #486 among its holdings.

188 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

  • Point72 Europe held 6,719 shares of Esperion Therapeutics worth $17.8K as of Q3 2025.
  • Esperion Therapeutics was a new Point72 Europe position in Q3 2025.
  • Esperion Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #486 holding.
  • 188 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.